GeoVax Labs (GOVX) Q1 2025 earnings summary

Executive summary

• Advanced development of GEO-CM04S1 (multi-antigen COVID-19 vaccine), GEO-MVA (mpox/smallpox vaccine), and Gedeptin (oncology) remains on track, with a focus on unmet medical needs and expedited registration paths.

• GeoVax Labs is a clinical-stage biotech focused on vaccines and immunotherapies for infectious diseases and cancers, with lead programs in COVID-19, head and neck cancer, and Mpox/smallpox.

• Strategic expansion into the UK and new VP hire to support product authorization and commercialization.

• BARDA terminated the Project NextGen contract for convenience, with minimal financial impact and no effect on ongoing clinical trials or perceived product safety/efficacy.

• Net loss for Q1 2025 was $5.4 million ($0.45/share), improved from $5.9 million ($2.47/share) in Q1 2024.

Financial highlights

• Q1 2025 revenues were $1.6 million, all from the BARDA contract, compared to $0 in Q1 2024.

• Research and development expenses rose 21% year-over-year to $5.4 million, mainly due to BARDA, Gedeptin, and GEO-MVA program costs.

• General administrative expenses increased 16% to $1.7 million, driven by investor relations and stock-based compensation.

• Cash balance at March 31, 2025, was $7.4 million, up from $5.5 million at year-end, reflecting $7.9 million in financing.

• Weighted average shares outstanding increased to 11.95 million in Q1 2025 from 2.37 million in Q1 2024.

Outlook and guidance

• Ongoing clinical trials for GEO-CM04S1 in immunocompromised populations remain a top priority, with multiple data readouts and conference presentations expected in 2025.

• GEO-MVA clinical evaluation is planned for later in 2025, with sufficient product manufactured for trials and stakeholder discussions.

• Gedeptin phase II trial in head and neck cancer is progressing, with additional studies planned for other solid tumors.

• Existing cash is expected to fund operations into Q3 2025; substantial doubt remains about the company's ability to continue as a going concern without additional capital.

• Management plans to seek further funding through equity, debt, grants, or partnerships.